EXICURE, INC. Current Federal Tax Expense (Benefit)
EXICURE, INC. (XCUR) reported Current Federal Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentFederalTaxExpenseBenefit · last filed 2026-03-25
- EXICURE, INC. current federal tax expense (benefit) for fiscal 2025 was $0.00.
- EXICURE, INC. current federal tax expense (benefit) for fiscal 2024 was $0.00.
- EXICURE, INC. current federal tax expense (benefit) for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- EXICURE, INC. current federal tax expense (benefit) for fiscal 2022 was $115.00K.
| Period end | Current Federal Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-25 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-25 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-18 |
| 2022-12-31 | $115.00K 10-K · filed 2024-06-06 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |